Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study.
BACKGROUND
Oral contraceptives are still associated with high discontinuation rates, despite their efficacy. There is a wide choice of oral contraceptives available, and the aim of this study was to assess continuation rates, bleeding profile acceptability, and the satisfaction of women in the first year of using a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) versus a progestogen-only pill (POP) in a real-life setting after discontinuing an ethinylestradiol-containing pill.


RESULTS
In this prospective, noninterventional, observational study, 3,152 patients were included for the efficacy analyses (n=2,558 women in the E2V/DNG group and n=592 in the POP group (two patients fulfilled the criteria of the efficacy population, but the used product was not known). Women had been taking an ethinylestradiol-containing pill ≥3 months before deciding to switch to the E2V/DNG pill or a POP. Overall, 19.8% (n=506) of E2V/DNG users and 25.8% (n=153) of POP users discontinued their prescribed pill. The median time to discontinuation was 157.0 days and 127.5 days, respectively. Time to discontinuation due to bleeding (P<0.0001) or other reasons (P=0.022) was significantly longer in the E2V/DNG group versus the POP group. The E2V/DNG pill was also associated with shorter (48.7% vs 44.1%), lighter (54% vs 46.1%), and less painful bleeding (91.1% vs 73.7%) and greater user satisfaction (80.7% vs 64.6%) than POP use, within 3-5 months after switch.


CONCLUSIONS
The E2V/DNG pill was associated with higher rates of continuation, bleeding profile acceptability, and user satisfaction than POP use and may be an alternative option for women who are dissatisfied with their current pill.
Sexual and Reproductive Health, Southport and Ormskirk Hospital NHS Trust, Merseyside, UK.
Paula
P
Briggs
Global Medical Affairs Women's HealthCare, Bayer Pharma AG, Berlin.
Marco
M
Serrani
Global Integrated Analysis & Life Cycle Management Statistics, Bayer Pharma AG, Wuppertal.
Kai
K
Vogtländer
Global Clinical Development Women's HealthCare, Bayer Pharma AG, Berlin, Germany.
Susanne
S
Parke
compliance; contraception; dienogest; estradiol valerate; oral contraceptive
J Obstet Gynaecol. 2013 Aug;33(6):591-6
23919857
Hum Reprod. 2009 Jun;24(6):1387-92
19252195
Eur J Contracept Reprod Health Care. 2011 Aug;16(4):258-69
21774563
Ann Pharmacother. 2011 Oct;45(10):1256-61
21917554
Cochrane Database Syst Rev. 2013 Nov 13;(11):CD007541
24226383
Int J Gynaecol Obstet. 2014 Jun;125(3):270-4
24713413
J Sex Med. 2013 Dec;10(12):3069-79
24034466
Eur J Contracept Reprod Health Care. 2013 Aug;18(4):274-83
23638631
Eur J Contracept Reprod Health Care. 2009 Jun;14(3):221-32
19565420
Med Clin North Am. 2015 May;99(3):479-503
25841596
Contraception. 1995 May;51(5):283-8
7628201
Cochrane Database Syst Rev. 2011 May 11;(5):CD004861
21563141
Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):577-82
9757954
Multivariate Behav Res. 2011 May;46(3):399-424
21818162
Best Pract Res Clin Endocrinol Metab. 2013 Feb;27(1):3-12
23384741
Cochrane Database Syst Rev. 2013 Aug 01;(8):CD003989
23904209
Eur J Obstet Gynecol Reprod Biol. 2010 Mar;149(1):57-62
19969409
Hum Reprod. 1996 Oct;11 Suppl 2:20-3
8982741